Sie suchten nach: eular response (Englisch - Estnisch)

eular response (%)
eular vastus (%)

response
vastus

& response
& vasta

response rate
ravivastuse määr

response duration
ravivastuse kestus

written response.
kirjalik vastus.

haematological response (%)
hematoloogiline ravivastus (%)

eular good/ moderate
eular hea/ mõõdukas

acr/eular index remission, n (%)
acr/eular indeksipõhine remissioon, n (%)

week 24: acr/eular boolean remission, n (%)
nädal 24: acr/eular boole’i remissioon, n (%)

a good to moderate european league against rheumatism (eular) response was achieved by significantly more rituximab treated patients compared to patients treated with methotrexate alone (table 9).
hea kuni mõõduka euroopa reumavastase liiga (eular) vastuse saavutas oluliselt rohkem rituksimabiga kui ainult metotreksaadiga ravitud patsiente (tabel 9).

similarly, a good to moderate european league against rheumatism (eular) response was achieved by significantly more mabthera treated patients treated with mabthera and methotrexate compared to patients treated with methotrexate alone (table 10).
sarnaselt saavutas kõikides uuringutes hea kuni mõõduka euroopa reumavastase liiga (eular) vastuse saavutas oluliselt rohkem mabthera’t ja metotreksaati saanud kui ainult metotreksaadiga ravitud patsiente (tabel 10).

similarly, in all studies a good to moderate european league against rheumatism (eular) response was achieved by significantly more mabthera treated patients treated with mabthera and methotrexate compared to patients treated with methotrexate alone (table 10).
sarnaselt saavutas kõikides uuringutes hea kuni mõõduka euroopa reumavastase liiga (eular) vastuse saavutas oluliselt rohkem mabthera’t ja metotreksaati saanud kui ainult metotreksaadiga ravitud patsiente (tabel 10).

in this study, acr/eular remission (boolean and index) were also analysed as pre-specified exploratory endpoints, with higher responses observed in the tocilizumab groups.
selles uuringus analüüsiti ettemääratud uurivate tulemusnäitajatena ka acr/eular remissiooni (boole’i ja indeksipõhine remissioon), mille saavutamise määr oli suurem totsilizumabi rühmades.